Joint (NASDAQ:JYNT – Get Free Report) and Guardant Health (NASDAQ:GH – Get Free Report) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, valuation, dividends, institutional ownership and earnings.
Profitability
This table compares Joint and Guardant Health’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Joint | 6.49% | 12.02% | 3.47% |
| Guardant Health | -38.33% | N/A | -25.40% |
Valuation & Earnings
This table compares Joint and Guardant Health”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Joint | $54.90 million | 2.02 | $2.91 million | $0.27 | 29.07 |
| Guardant Health | $982.02 million | 21.51 | -$416.28 million | ($3.49) | -45.09 |
Joint has higher earnings, but lower revenue than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Joint, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a breakdown of recent ratings and price targets for Joint and Guardant Health, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Joint | 0 | 3 | 0 | 0 | 2.00 |
| Guardant Health | 1 | 0 | 24 | 1 | 2.96 |
Guardant Health has a consensus target price of $188.12, indicating a potential upside of 19.54%. Given Guardant Health’s stronger consensus rating and higher possible upside, analysts clearly believe Guardant Health is more favorable than Joint.
Risk and Volatility
Joint has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.57, suggesting that its share price is 57% more volatile than the S&P 500.
Institutional and Insider Ownership
76.9% of Joint shares are held by institutional investors. Comparatively, 92.6% of Guardant Health shares are held by institutional investors. 30.2% of Joint shares are held by company insiders. Comparatively, 5.6% of Guardant Health shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Guardant Health beats Joint on 8 of the 15 factors compared between the two stocks.
About Joint
The Joint Corp. operates and franchises chiropractic clinics in the United States. The company operates in two segments, Corporate Clinics and Franchise Operations. The Joint Corp. was incorporated in 2010 and is headquartered in Scottsdale, Arizona.
About Guardant Health
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
Receive News & Ratings for Joint Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Joint and related companies with MarketBeat.com's FREE daily email newsletter.
